1.

L'initiative pour la promotion de la qualite et epidemiologie du diabete sucre (IPQED). ; Initiave to promote quality of care and epidemiology of diabetes mellitus

1.

Belgian expert opinion: how to reduce the residual risk in atherogenic dyslipidaemic patients: place of fibrates.

2.

Belgian expert opinion: how to reduce the residual risk in atherogenic dyslipidaemic patients: place of fibrates.

3.

Belgian expert opinion: how to reduce the residual risk in atherogenic dyslipidaemic patients: place of fibrates.

1.

Increased risk of primary hypothyroidism in preterm infants.

1.

Inhibiteurs des SGLT2 chez les patients avec insuffisance rénale chronique : des essais contrôlés aux recommandations internationales et perspectives en pratique clinique. ; SGLT2...

1.

Instauration et optimisation d'une insulinothérapie en médecine générale : InsuStar, une étude observationnelle prospective belge dans le diabète de type 2 ; Initiating and intensi...

2.

Instauration et optimisation d'une insulinothérapie en médecine générale : InsuStar, une étude observationnelle prospective belge dans le diabète de type 2 ; Initiating and intensi...

3.

Instauration et optimisation d'une insulinothérapie en médecine générale : InsuStar, une étude observationnelle prospective belge dans le diabète de type 2 ; Initiating and intensi...

1.

Organization of a quality-assurance project in all Belgian multidisciplinary diabetes centres treating insulin-treated diabetes patients: 5 years' experience.

2.

Organization of a quality-assurance project in all Belgian multidisciplinary diabetes centres treating insulin-treated diabetes patients: 5 years' experience.

3.

Organization of a quality-assurance project in all Belgian multidisciplinary diabetes centres treating insulin-treated diabetes patients: 5 years' experience.

1.

Le medicament du mois. Combinaison fixe ezetimibe-rosuvastatine (Myrosor(R)). ; Ezetimibe-rosuvastatin fixed-dose combination (Myrosor(R))

1.

Growth response of syndromic versus non-syndromic children born small for gestational age (SGA) to growth hormone therapy: a Belgian study.

2.

Growth response of syndromic versus non-syndromic children born small for gestational age (SGA) to growth hormone therapy: a Belgian study.

3.

Growth response of syndromic versus non-syndromic children born small for gestational age (SGA) to growth hormone therapy: a Belgian study.

1.

Le medicament du mois. Sitagliptine (Januvia): incretinopotentiateur indique comme insulinosecretagogue dans le traitement du diabete de type 2. ; Sitagliptine (Januvia): incretin...

1.

Les nouvelles recommandations Europeennes pour le traitement des dyslipidemies en prevention cardiovasculaire. ; New European guidelines for the management of dyslipidaemia in card...